Media
Corgentech Announces Its Initial Public Offering
(SOUTH SAN FRANCISCO, Calif., February 12, 2004) -- Corgentech Inc. announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a price to the public of $16 per share. All of the shares are being offered by Corgentech. Corgentech has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock to cover over-allotments, if any. Corgentech's common stock will be listed on the Nasdaq National Market under the symbol "CGTK."
The underwriters of the offering are Credit Suisse First Boston and Lehman Brothers, acting as joint book-running managers, and CIBC World Markets and Piper Jaffray & Co., acting as co-managers.
Copies of the final prospectus related to the offering may be obtained from the prospectus department of either Credit Suisse First Boston LLC (One Madison Avenue, New York, New York 10010; 212-325-2580) or Lehman Brothers Inc., Prospectus Department (c/o ADP Financial Services, Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, New York 11717; 631-254-7106).
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Corgentech Inc.
Corgentech Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF Decoys, for the treatment of cardiovascular disease, inflammatory disease, and cancer.
